[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609982":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":10,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients provide blood samples collected during regularly scheduled appointments and have medical records reviewed throughout the study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Non-Interventional Study","Non-interventional study",[9],[20,21],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[23],{"name":24,"affiliation":25,"role":26},"Madeleine B. O'Keefe, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[34],{"facility":25,"status":10,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Rochester","Minnesota","55905","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-92.4699,44.02163,{"lat":44,"lon":43},[47,48,51],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":49,"role":30,"phone":50,"phoneExt":10,"email":10},"Pediatric Research","507-266-2942",{"name":24,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100609982","evaluation-of-prolonged-asparaginase-activity-levels-after-calaspargase-pegol-administration-100609982",false,"NCT07221656","Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration","Inclusion Criteria:\n\n* Acute lymphoblastic leukemia\u002Flymphoma being treated by the pediatric hematology team\n* Receiving calaspargase as part of treatment for malignancy\n\nExclusion Criteria:\n\n* Age \\> 21 years\n* Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm\n* Pregnancy","ALL","21 Years",{"count":63,"type":64},20,"ESTIMATED","OBSERVATIONAL","This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.",[68,69],"Childhood Acute Lymphoblastic Leukemia","Childhood Lymphoblastic Lymphoma","NOT_YET_RECRUITING","2026-03-31",{"date":73,"type":74},"2026-04-02","ACTUAL",{"date":76,"type":64},"2027-02-01",{"date":78,"type":64},"2028-12-31",{"name":5,"class":6},1]